Welcome to our dedicated page for Sunshine Biopharma news (Ticker: SBFM), a resource for investors and traders seeking the latest updates and insights on Sunshine Biopharma stock.
Sunshine Biopharma Inc. (NASDAQ: SBFM) generates news across commercial pharmaceuticals, biosimilars, and biotechnology research. Through its Canadian subsidiary Nora Pharma Inc., the company announces launches and regulatory milestones for generic prescription drugs and biosimilars in Canada, while its internal pipeline produces updates on mRNA-based oncology candidates and antiviral small-molecule programs.
Readers following SBFM news can expect coverage of generic drug launches in key therapeutic categories. Recent announcements include the commercialization of gabapentin for neuropathic pain and epilepsy, doxycycline for a range of bacterial and tick-borne infections, pravastatin for cholesterol management and cardiovascular risk reduction, and domperidone for nausea, vomiting, and gastrointestinal motility, including chemotherapy-induced nausea and vomiting. These items often highlight Health Canada authorizations, product indications, dosage forms, and Sunshine Biopharma’s growing catalog of more than 70 generic prescription drugs in Canada.
News flow also covers Sunshine Biopharma’s entry into biosimilars with NIOPEG, a biosimilar comparable to NEULASTA (pegfilgrastim) used to reduce infection risk in cancer patients receiving chemotherapy. Articles describe the significance of this launch for the company’s presence in the biologics market and its focus on oncology-related supportive care.
On the research side, Sunshine Biopharma issues updates on its K1.1 mRNA liver cancer program and its PLpro protease inhibitor program for SARS coronavirus infections, including preclinical data, collaborations with the University of Arizona, and publication of results in scientific journals. Additional corporate news may address treasury and capital allocation decisions, such as the board-approved $5 million strategic reserve allocation to Bitcoin, as well as commentary on the company’s broader strategy combining generics, biosimilars, and proprietary R&D.
For investors and observers, the SBFM news page offers a consolidated view of product launches, regulatory clearances, scientific milestones, and financial strategy updates. It is a useful resource for tracking how Sunshine Biopharma’s commercial activities and research programs evolve over time.
Sunshine Biopharma, Inc. (SBFM, SBFMW) announced a securities purchase agreement generating approximately $8.0 million from institutional and accredited investors. The offering involves 3,603,604 units priced at $2.22 each, with each unit consisting of a share of common stock and a non-tradable warrant. The closing is expected around March 14, 2022. Sunshine Biopharma is developing treatments for COVID-19 and various cancers, including its lead compound SBFM-PL4 and anticancer drug Adva-27a, with clinical trials planned in collaboration with prestigious institutions.
Sunshine Biopharma has announced an agreement with the University of Arizona to advance the development of novel PLpro inhibitors. These inhibitors aim to combat SARS-CoV-2 by determining safety and efficacy in preclinical models, specifically MA10 mice. The lead compound, SBFM-PL4, is also undergoing further development at the University of Georgia. The initiative is a crucial step in enhancing treatment options against COVID-19, as highlighted by the company's CEO, Dr. Steve Slilaty.
Aegis Capital Corp. acted as the sole bookrunner for Sunshine Biopharma Inc.'s $8 million underwritten public offering, aimed at supporting the development of its COVID-19 therapeutic SBFM-PL4 and anticancer compound Adva-27a. Sunshine Biopharma is focused on creating treatments for COVID-19 and aggressive forms of cancer, including pancreatic cancer. The company is moving forward with clinical trials for Adva-27a, which has shown effectiveness against multidrug-resistant cancer cells. This offering could potentially enhance Sunshine Biopharma's financial position as it seeks to progress its research and development initiatives.
Sunshine Biopharma announced the completion of its public offering of 1,882,353 units at $4.25 each, raising $8 million in gross proceeds. Each unit comprises one share of common stock and two warrants, both exercisable at $4.25. Aegis Capital Corp. managed the offering and was granted a 45-day option to purchase additional securities. The company is advancing SBFM-PL4, a lead compound for COVID-19 treatment, and preparing for clinical trials of Adva-27a, an anticancer drug targeting multidrug-resistant cancer cells.
Sunshine Biopharma, focused on oncology and antiviral drug development, has priced its public offering of 1,882,353 units at $4.25 each, totaling $8 million. Each unit comprises one share of common stock and two warrants, immediately separable for trading. Aegis Capital is the sole book-running manager and holds a 45-day option for an additional 15% of shares and warrants. The offering will close around February 17, 2022. Sunshine Biopharma's common stock and warrants have been approved for listing on the Nasdaq under symbols SBFM and SBFMW.
On December 20, 2021, Sunshine Biopharma (SBFM) issued 2,904,833 shares of Common Stock to RB Capital, converting $1,361,000 in convertible debt at an average price of $0.47 per share. The remaining convertible debt totals $1,900,000 at an average conversion price of $0.30, with maturity dates in 2023. This move is expected to enhance the company's financial position while conserving cash for ongoing research in antiviral and anticancer drug development. Key projects include SBFM-PL4, a potential COVID-19 treatment, and Adva-27a, targeting multidrug-resistant cancers.
Sunshine Biopharma (OTC PINK: SBFM) has expanded its board from three to five members by appointing three new independent directors: Andrew Tesley, JD Kish, and Dr. Rabi Kiderchah. This strategic move is part of the company's application process to uplist to Nasdaq. The new directors bring valuable expertise in legal, accounting, and medical fields. Mr. Camille Sebaaly has resigned as a director but will continue as CFO. Sunshine Biopharma is advancing treatments for COVID-19 and cancer, including ongoing studies on potential inhibitors of SARS-CoV-2 and the anticancer drug Adva-27a.
Sunshine Biopharma (SBFM) has filed a patent application for a novel treatment targeting neurodegenerative disorders. This application, dated October 1, 2021, presents data indicating that specific mRNA molecules can protect neuronal cells from oxidative stress, a condition mimicking neuronal degeneration. Neurodegenerative diseases affect millions globally, with no known cures. The company aims to develop a therapeutic approach that could potentially alleviate symptoms and halt disease progression.
Sunshine Biopharma (SBFM) announced significant advancements in its drug development for COVID-19 and cancer therapies. The company mapped mutations from Delta and other variants, finding that most mutations affect the Spike protein, leaving their PLpro inhibitors likely effective against ongoing variants. The lead compound, SBFM-PL4, is being tested in mice engineered to be susceptible to SARS-CoV-2. Additionally, Sunshine Biopharma is progressing with Adva-27a, an anticancer compound, demonstrating effectiveness against multidrug-resistant cancer cells. Clinical trials for pancreatic cancer are planned.
Sunshine Biopharma (SBFM) has launched an official Twitter account (@SunshineBio1) to enhance communication with shareholders, following feedback regarding preferred engagement methods. The company aims to utilize this platform for timely updates, recognizing the importance of transparency in modern information dissemination. Sunshine Biopharma is advancing potential Covid-19 treatments and developing the anticancer compound Adva-27a. While the company emphasizes shareholder engagement, it also acknowledges the inherent risks and uncertainties in meeting financial expectations and achieving profitability.